Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Monday. The firm set a “hold” rating on the stock.

A number of other research analysts have also recently commented on the stock. HC Wainwright dropped their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Lake Street Capital dropped their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th.

Ekso Bionics Stock Performance

Shares of NASDAQ:EKSO opened at $0.73 on Monday. Ekso Bionics has a 1 year low of $0.50 and a 1 year high of $3.03. The stock has a market capitalization of $16.06 million, a price-to-earnings ratio of -1.12 and a beta of 1.47. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The company’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $0.97.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. During the same period in the prior year, the business posted ($0.24) EPS. As a group, research analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.